ABSTRACT

Introduction

Meningococcal disease caused by Neisseria meningitidis is a major cause of meningitis and septicemia with high rates of morbidity and mortality worldwide. MenACWY-TT and MenACWY-CRM₁₉₇ are meningococcal conjugate vaccines approved for use in children and adults in the UK. The aim of this review was to evaluate and compare antibody responses and persistence in different age groups after MenACWY-TT and MenACWY-CRM₁₉₇.

Areas covered

Randomized trials showed that MenACWY-TT is immunogenic at all ages. MenACWY-CRM₁₉₇ is immunogenic for infants and adults, but there is a lack of data for children aged 1 to 2 years. Studies on MenACWY-TT indicated that serum bactericidal antibody (SBA) utilizing baby rabbit complement (rSBA) titers were significantly higher and more stable than SBA using human complement (hSBA) titers, compared with hSBA titers, which were lower and declined more rapidly by 1 year following post-primary MenACWY-TT and MenACWY-CRM₁₉₇ vaccination, especially for MenA.

Expert opinion

MenACWY-TT and MenACWY-CRM₁₉₇ are both well tolerated and induce similar antibody persistence and immunogenicity against all four serogroups for individuals more than one year old. rSBA assay is a more robust assay than the hSBA assay when vaccinating with MenACWY-TT, while rSBA and hSBA assays had similar antibody persistence when vaccinating with MenACWY-CRM₁₉₇.

中文翻译：

---

脑膜炎球菌ACWY偶联疫苗在欧洲联盟中按年龄组和疫苗许可后的抗体持久性。

摘要

介绍

由脑膜炎奈瑟氏球菌引起的脑膜炎球菌病是脑膜炎和败血病的主要原因，在世界范围内发病率和死亡率很高。MenACWY-TT和MenACWY-CRM ₁₉₇是在英国获准用于儿童和成人的脑膜炎球菌结合疫苗。这篇综述的目的是评估和比较MenACWY-TT和MenACWY-CRM ₁₉₇后不同年龄组的抗体应答和持久性。

覆盖区域

随机试验表明，MenACWY-TT在所有年龄段均具有免疫原性。MenACWY-CRM ₁₉₇具有婴儿和成人的免疫原性，但缺乏1至2岁儿童的数据。MenACWY-TT的研究表明，与使用人补体（hSBA）效价的SBA相比，利用小兔补体（rSBA）效价的血清杀菌抗体（SBA）显着更高和更稳定，而hSBA效价则更低且下降更快。初次接种MenACWY-TT和MenACWY-CRM ₁₉₇后1年，尤其是MenA。

专家意见

MenACWY-TT和MenACWY-CRM ₁₉₇均具有良好的耐受性，并且对于超过一岁的个体，针对所有四个血清群均具有相似的抗体持久性和免疫原性。用MenACWY-TT疫苗接种时，rSBA分析比hSBA分析更可靠，而用MenACWY-CRM ₁₉₇接种时rSBA和hSBA分析具有相似的抗体持久性。